Skip to content
Contact
About PORTAL
Our Team
Our Work
Innovation Incentives and Competition
Regulation and Clinical Evidence
Price, Value, and Access
Search Our Library
From “Price Controls” to Robust Public Conversation: How CMS Can Move Drug Price Negotiation Into the Light
HOME
/
Commentary & Opinion
/
From “Price Controls” to Robust Public Conversation: How CMS Can Move Drug Price Negotiation Into the Light